European Medicines Agency and US Food and Drug Administration receive first parallel quality-by-design application

17.06.2011
European Medicines Agency and US Food and Drug Administration receive first para
EMA

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have agreed to accept the first application under their pilot programme for the parallel evaluation of marketing-authorisation applications involving 'quality by design' (QbD). 

Read more on the EMA website.